|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.22 USD | +0.79% |
|
+4.93% | +5.33% |
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
Selling General & Admin Expenses, Total | 3.86M | 6.98M | 10.98M | 19.2M |
R&D Expenses | 21.3M | 28.33M | 57.22M | 78.86M |
Other Operating Expenses, Total | 25.16M | 35.31M | 68.19M | 98.06M |
Operating Income | -25.16M | -35.31M | -68.19M | -98.06M |
Interest Expense, Total | -374K | - | - | - |
Interest And Investment Income | 345K | 1.7M | 3.34M | 7.47M |
Net Interest Expenses | -29K | 1.7M | 3.34M | 7.47M |
Other Non Operating Income (Expenses) | -73K | - | - | - |
EBT, Excl. Unusual Items | -25.26M | -33.61M | -64.85M | -90.58M |
Gain (Loss) On Sale Of Investments | 27K | 1.04M | 2.93M | 3.61M |
Other Unusual Items | -899K | - | - | - |
EBT, Incl. Unusual Items | -26.14M | -32.56M | -61.92M | -86.97M |
Earnings From Continuing Operations | -26.14M | -32.56M | -61.92M | -86.97M |
Net Income to Company | -26.14M | -32.56M | -61.92M | -86.97M |
Net Income - (IS) | -26.14M | -32.56M | -61.92M | -86.97M |
Net Income to Common Incl Extra Items | -26.14M | -32.56M | -61.92M | -86.97M |
Net Income to Common Excl. Extra Items | -26.14M | -32.56M | -61.92M | -86.97M |
Per Share Items | ||||
Net EPS - Basic | -39.18 | -31.96 | -5.82 | -2.38 |
Basic EPS - Continuing Operations | -39.18 | -31.96 | -5.82 | -2.38 |
Basic Weighted Average Shares Outstanding | 667K | 1.02M | 10.64M | 36.51M |
Net EPS - Diluted | -39.18 | -31.96 | -5.82 | -2.38 |
Diluted EPS - Continuing Operations | -39.18 | -31.96 | -5.82 | -2.38 |
Diluted Weighted Average Shares Outstanding | 667K | 1.02M | 10.64M | 36.51M |
Normalized Basic EPS | -23.67 | -20.62 | -3.81 | -1.55 |
Normalized Diluted EPS | -23.67 | -20.62 | -3.81 | -1.55 |
Supplemental Items | ||||
EBITDA | -25.1M | -35.15M | -67.95M | -97.81M |
EBITA | -25.16M | -35.31M | -68.19M | -98.06M |
EBIT | -25.16M | -35.31M | -68.19M | -98.06M |
EBITDAR | -25M | -34.95M | -67.75M | -97.51M |
Normalized Net Income | -15.79M | -21M | -40.53M | -56.61M |
Supplemental Operating Expense Items | ||||
General and Administrative Expenses | 3.76M | 6.78M | 10.78M | 18.9M |
Research And Development Expense From Footnotes | 21.4M | 28.53M | 57.42M | 79.16M |
Net Rental Expense, Total | 100K | 200K | 200K | 300K |
Stock-Based Comp., R&D Exp. (Total) | 93K | 904K | 2.54M | 3.56M |
Stock-Based Comp., G&A Exp. (Total) | 213K | 1.14M | 2.68M | 5.11M |
Total Stock-Based Compensation | 306K | 2.04M | 5.22M | 8.68M |
- Stock Market
- Equities
- MBX Stock
- Financials MBX Biosciences, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















